{"transactions":[{"id":710121,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO"}}],"security":"Restricted stock Units","published_at":"2026-07-14T20:00:22.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 10, 2026, the reporting person was granted 1,500 restricted stock units (\"RSUs\"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."}],"balance_after":1500,"derivative":{"exercise_price":0,"underlying":"Series A Preferred Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001493152-26-033168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226033168/ownership.xml","form_type":"4"}},{"id":2576518,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Options","published_at":"2021-09-08T21:00:37.000Z","date":"2021-09-03","kind":"grant","acquired":true,"shares":675000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock Options vest as follows: (i) 50% of the options will vest upon the consummation of a qualifying joint venture agreement, licensing agreement, or acquisition transaction (a \"Corporate Transaction\"); (ii) The remaining 50% on the one-year anniversary of the consummation of a Corporate Transaction."}],"balance_after":675000,"derivative":{"exercise_price":0.1393,"expiration_date":"2031-09-03","underlying":"Common Stock","underlying_shares":675000},"source":{"system":"sec-edgar","filing":"0001493152-21-022217","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221022217/ownership.xml","form_type":"4"}},{"id":2632511,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Options","published_at":"2021-07-16T21:35:47.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":216279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant."}],"balance_after":216279,"derivative":{"exercise_price":0.1626,"exercise_date":"2021-07-08","expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":216279},"source":{"system":"sec-edgar","filing":"0001493152-21-017102","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017102/ownership.xml","form_type":"4"}},{"id":2632510,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:35:47.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":16355,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the \"Merger\"), shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the \"Merger\"), shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the \"Merger\"), shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16354961},"source":{"system":"sec-edgar","filing":"0001493152-21-017102","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017102/ownership.xml","form_type":"4"}},{"id":2632509,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2021-07-16T21:35:47.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":102519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant."}],"balance_after":16457480,"source":{"system":"sec-edgar","filing":"0001493152-21-017102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017102/ownership.xml","form_type":"4"}},{"id":2632508,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2021-07-16T21:35:47.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":16354961,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the \"Merger\"), shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":16354961,"source":{"system":"sec-edgar","filing":"0001493152-21-017102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017102/ownership.xml","form_type":"4"}}]}